Lilly and BioMS Medical Announce Global Licensing and Development...(ed that MBP8298 safely delayed median ti...)

Date:12/17/2007

ed that MBP8298 safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, MBP8298 has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.
MBP8298 is being developed in three late-stage clinical trials:

-- MAESTRO-01: A pivotal phase II/III trial for secondary progressive MS

(SPMS) patients in Canada and Europe.

-- MAESTRO-03: A pivotal phase III trial for SPMS patients in the United

States.

-- MINDSET-01: A phase II trial for relapsing-remitting MS (RRMS)

patients in Europe.

About Multiple Sclerosis

Multiple sclerosis (MS) is thought to affect as many as 2.5 million people worldwide, including approximately 75,000 in Canada, 400,000 in the United States and more than 500,000 in Europe. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 years of age. MS is caused by damage to myelin, the protective sheath surrounding nerve fibers in the central nervous system, which interferes with messages from the brain to the body. Symptoms of MS may include vision problems, loss of balance, numbness, difficulty walking and paralysis. Approximately 40 percent of all MS patients have the secondary progressive form of the disease.

BioMS Medical Conference Call

BioMS Medical management will host a conference call at 8:30 a.m. (EST) on Tuesday December 18, 2007 to discuss the global licensing and development agreement with Lilly. Participants may listen via an audio web cast, accessible through the Company's website at http://www.biomsmedical.com or via telephone. The telephone conference number is 416-644-3420 or toll-free at 1-800-731-6941.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growi
'/>"/>

SOURCE Eli Lilly and Company Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. BioMS Medical announces its intention to renew a normal course issuer bid
5. BioMS Medical to present at BioContact 2007
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
8. BioMS Medical announces third quarter 2007 results
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
11. AEterna Zentaris completes management team with the appointment of Chief Medical Officer